Skip to content
Biotechnology

New tool enables early intervention for diabetic foot ulcers

RMIT University 2 mins read

Australian researchers and clinicians have developed an AI-powered thermal imaging tool to predict if diabetes-related foot ulcers are likely to heal, potentially reducing hospitalisations and amputations. 

Diabetes affects over 500 million people globally and about a third will develop a foot ulcer during their life, which can lead to infection, hospitalisation and amputation if not managed appropriately. 

Clinical guidelines assess progress over the first four weeks of treatment to determine whether an ulcer is healing. 

Now a study in the Journal of Diabetes Science and Technology introduces a new smartphone-based AI tool, called THERMUL, that provides clinicians with an indication of healing risk much earlier, using thermal images captured when a patient first presents for care. 

The researchers from RMIT University, the University of Melbourne and Bolton Clarke conducted a clinical study at Austin Health and St Vincent’s Hospital Melbourne involving 110 patients with diabetes-related foot ulcers. 

Using a light-weight thermal camera, researchers took images of the patients' ulcers when they initially presented to the clinic, with additional images captured two and four weeks later. 

At 12 weeks, clinicians assessed whether each ulcer had healed, allowing the research team to compare healing outcomes with the thermal image data collected earlier. 

RMIT’s Professor Dinesh Kumar lead the development of THERMUL with Endocrinologist Professor Elif Ekinci, Head of the University of Melbourne’s Department of Medicine. 

Kumar said the researchers used the data to train the AI model to identify heat patterns associated with ulcers that healed successfully and those that did not. 

"These patterns may provide an early indication of a wound's likely healing trajectory, potentially allowing clinicians to identify people who might benefit from earlier intervention or escalation of care," said Kumar, from RMIT’s School of Engineering. 

Ekinci, who is also Director of the Australian Centre for Accelerating Diabetes Innovations (ACADI), said the technology has the potential to improve health equity and deliver economic benefits for Australia’s healthcare system. 

“Diabetes-related foot disease places a significant burden on individuals and the Australian health system, costing an estimated $875 million every year,” she said. 

“By enabling earlier identification of ulcers at risk of delayed wound healing, THERMUL has the potential to improve access to timely care and reduce complications.” 

Senior research fellow at Bolton Clarke, Dr Rajna Ogrin, said people in regional, rural and remote areas living with diabetes and receiving care at home, or through outreach services, may not have timely access to specialist diabetes foot services. 

"A portable, non-contact tool like THERMUL has the potential to bring specialist-level decision support closer to where people live and receive care," she said. 

Seed funding from ACADI enabled the research team to develop the prototype. 

The research team also recently received $490,539 through Australia’s Economic Accelerator program and $50,000 from the University of Melbourne’s Proof of Concept Fund. 

They will use this funding to validate the technology across a range of healthcare settings, including metropolitan, regional and remote services, and to further improve the predictive model. 

THERMUL is currently progressing through additional validation and development activities required to support future use in healthcare settings. 

Partner organisations include the Australian Centre for Accelerating Diabetes Innovations, Austin Health, Bolton Clarke, St Vincent’s Hospital Melbourne, Royal Flying Doctor Service Victoria and Software Medical Devices Pty Ltd.  

‘Automated prediction of Diabetes-related foot ulcer healing at initial assessment’ is published in the Journal of Diabetes Science and Technology (DOI: 10.1177/19322968261501979). 

 

Contact details:

Michael Quin

[email protected]

0499 515 417

Media

More from this category

  • Biotechnology, Medical Health Aged Care
  • 13/11/2026
  • 09:20
Aravax

Aravax Announces Positive Results of Phase 2 Clinical Trial of PVX108, a Novel Immunotherapy for the Treatment of Peanut Allergy

Melbourne, Australia, 13 November 2026— Aravax, a clinical‑stage biotechnology company developing next‑generation therapies for food allergy, today announces positive topline results in children from its Phase 2 clinical trial involving its lead product, PVX108 for the treatment of peanut allergy. PVX108 is an investigational, next-generation immunotherapy which uses proprietary peptides designed to precisely retrain the immune system to tolerate peanut whilst minimising treatment-induced acute allergic reactions. It has been awarded FDA Fast Track designation for the treatment of peanut allergy. Dr Pascal Hickey, CEO, Aravax said, “PVX108 is the first therapy designed to precisely target the root cause of peanut…

  • Biotechnology
  • 11/11/2026
  • 01:07
AGC Biologics, Inc.

AGC Biologics partners with Child’s Cure Genetic Research to pursue mRNA-based therapeutic for severe epileptic disorder

Demonstrates new evolution in mRNA to address rare conditionsCDMO’s work with parent-led, patient-focused foundation will investigate a development pathway to combat CDKL5 Deficiency DisorderAGC Biologics is well positioned to help advance mRNA programs toward the clinicHEIDELBERG, Germany, Nov. 10, 2026 (GLOBE NEWSWIRE) -- In a world where patients with CDKL5 deficiencies can suffer 40 to 60 epileptic seizures a day, a contract biopharmaceutical manufacturer and a parent-founded foundation will partner on early-stage messenger RNA development to find a long-term treatment for the rare neurodevelopmental disease. With few RNA-based programs in development for rare diseases, Child’s Cure Genetic Research and AGC…

  • Biotechnology
  • 05/11/2026
  • 19:22
ArrayPatch

ArrayPatch Completes Oversubscribed €3.2 Million Seed Financing to Advance Next-Generation Microneedle Therapeutics

CORK, Ireland, Nov. 05, 2026 (GLOBE NEWSWIRE) -- ArrayPatch Ltd (“ArrayPatch”), a biotech company developing innovative microneedle-based therapeutics, today announced the successful completion of the second close of its seed financing round, securing an additional €1.6 million, bringing the total raised to €3.2 million. The latest investment comes from impact-focused venture capital firm WakeUp Capital along with funds raised via Spark Venture Funding and Dr. Mark Ledwidge plus existing lead investor Lakeside Capital and DeepIE Ventures.The proceeds from the seed financing will be used to accelerate the development of programs leveraging its proprietary DerMap™ dissolving microneedle patch platform towards first-in-human studies,…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.